Study details
Enrolling now
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Gilead Sciences
NCT IDNCT06029972ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
176
Study length
about 3.5 years
Ages
18–75
Locations
53 sites in AZ, CA, FL +12
About this study
This trial is testing if tilpisertib fosmecarbil, a medication, can help people with moderately to severely active ulcerative colitis. It compares participants treated with tilpisertib fosmecarbil to those treated with a placebo.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Tilpisertib Fosmecarbil
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low5%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Body systems
Gastroenterology